The Impact of Selpercatinib 40 & 80 mg on RET-Positive Cancers
Selpercatinib, available in 40 mg and 80 mg doses, has revolutionized the treatment of RET-positive cancers, such as non-small cell lung cancer and medullary thyroid cancer. By specifically targeting RET gene alterations, Selpercatinib offers improved efficacy and reduced side effects compared to tr
0 views • 6 slides
Breakthrough Cancer Therapy in India: Selpercatinib 40 80 mg for RET Mutations
Selpercatinib 40 & 80 mg is an innovative targeted therapy designed to inhibit RET gene mutations, providing a highly precise treatment option for patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancers. Now available as Selpercatinib
0 views • 11 slides